and Emerging Targets in Oncology

Current Treatment Landscape for Cancer

BiTE® Immuno-Oncology Platform

Investigational Targets with the BiTE® Platform in Hematologic Malignancies: Multiple Myeloma and B-Cell Maturation Antigen (BCMA)

Investigational Targets with the BiTE® Platform in Solid Malignancies: Prostate Cancer and Prostate-Specific Membrane Antigen (PSMA)

Additional Emerging Targets for Investigation With the BiTE® Immuno-Oncology Platform

Meet the Speaker

Ajai Chari, MD

Mount Sinai School of Medicine

Program Objectives


The design of the BiTE® technology1


The potential of the BiTE® platform to target a range of tumors2


The major milestones in cancer treatment3,4


The cancer treatment landscape and how it has evolved with immuno-oncology therapies5


  1. Yuraszeck T, Kasichayanula S, Benjamin JE. Translation and clinical development of bispecific T-cell engaging antibodies for cancer treatment. Clin Pharmacol Ther. 2017;101(5):634-645.
  2. Amgen pipeline. Amgen website. Accessed October 17, 2019.
  3. Cancer progress timeline. ASCO website. Accessed October 17, 2019.
  4. Timeline of progress in immunotherapy. CRI website. Accessed October 17, 2019.
  5. Hoos A, Britten C. The immuno-oncology framework: Enabling a new era of cancer therapy. Oncoimmunology. 2012;1(3):334-339.

Dr. Chari did not accept an honorarium for this program.

Amgen Oncology logo

© 2019-2020 Amgen Inc. All rights reserved. USA-OCF-80650 08/2020